Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia. (CLL0911)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01762202|
Recruitment Status : Completed
First Posted : January 7, 2013
Last Update Posted : October 14, 2020
|Condition or disease||Intervention/treatment||Phase|
|B-cell Lymphoid Leukemia Young Patients||Drug: Cyclophosphamide Drug: Fludarabine Drug: Ofatumumab||Phase 2|
- rituximab, fludarabine and cyclophosphamide (FCR) front-line treatment was associated with a high OR rate, superior PFS and OS as compared to fludarabine and cyclophosphamide regimen;
- a direct relationship between the dose of rituximab and the response rate has been reported;
- ofatumumab, as single agent, proved activity in CLL patients with refractory disease;
- ofatumumab, fludarabine and cylophosphamide (O-FC) front-line treatment has been associated with a high complete response (CR) rate;
- the expected grade 3-4 granulocytopenia could led to reduce the dose intensity of study drugs (FC) and increase the infection rate; a schedule combining FC with an increased dose of ofatumumab associated to primary phrophylaxis of granulocytopenia could be associated with an improvement in the CR rate. The purpose of this study is to determine whether we could improve the CR rate of the golden standard treatment for fit patients with CLL , the FCR regimen, with a chemoimmunotherapy including FC combined with an increased dose of the monoclonal antibody ofatumumab, given every other week (FCO2) associated with a primary prophylaxis of granulocytopenia.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 2 Multicenter, Study to Assess the Efficacy and the Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab (FCO2) Chemoimmunotherapy in Young (≤65 Yrs) Patients With Chronic Lymphocytic Leukemia (CLL).|
|Actual Study Start Date :||November 5, 2013|
|Actual Primary Completion Date :||November 2015|
|Actual Study Completion Date :||October 2018|
|Experimental: Study therapy||
- Number of complete responses. [ Time Frame: After 8 months from study entry. ]The complete response (CR) rate after FCO2 front-line treatment.
- Number of overall responses. [ Time Frame: After 8 months from study entry. ]Overall Response (OR) rate after FCO2 front-line treatment.
- Number of patients in progression-free survival. [ Time Frame: After 32 months from study entry. ]Progression-free survival (PFS) calculated from the date of first treatment dose - induction phase - until the date of the first documentation of progressive disease or until death (whatever the cause), whichever occurs first. Patients still alive and known to be progression free will be censored at the moment of last follow-up.
- Number of patients needing a new CLL Treatment. [ Time Frame: After 32 months from study entry. ]Time to a new CLL treatment (TTT) will be calculated from the date of last treatment dose until date of a new treatment received for CLL, where death occurred before the new treatment will be considered as competing risk. Patients still alive without receiving a new treatment will be censored at the time of the last follow-up.
- Number of patients in overall survival [ Time Frame: After 32 months from study entry. ]Overall survival (OS): defined as the time interval between the date of first treatment dose - induction phase- and the date of death for any cause; patients still alive will be censored at the moment of last follow-up.
- Number of toxic events. [ Time Frame: After 32 months from study entry. ]Toxicity of treatment according the last NCI criteria.
- Outcome of patients according to clinical and biologica variables. [ Time Frame: After 32 months from study entry. ]Outcome of patients (response, PFS OS) according to clinical and biologic variables (age; size of nodes, 2-microglobulin, lymphocyte count, stage, IgVH, p53, FISH, ZAP-70, CD38, FLCs).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01762202
|Study Chair:||Roberto Foà, Pr.||Policlinico Umberto I, Hematology Department.|
|Study Director:||Francesca R. Mauro||Policlinico Umberto I, Hematology Department.|